Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-80.14%
0%
-80.14%
6 Months
-80.08%
0%
-80.08%
1 Year
-86.57%
0%
-86.57%
2 Years
-86.7%
0%
-86.7%
3 Years
1379.59%
0%
1379.59%
4 Years
1050.79%
0%
1050.79%
5 Years
1859.46%
0%
1859.46%
Tissue Regenix Group Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.08%
EBIT Growth (5y)
14.04%
EBIT to Interest (avg)
-2.01
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.35
Sales to Capital Employed (avg)
0.60
Tax Ratio
52.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
0.23%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.39
EV to EBIT
-15.67
EV to EBITDA
15.67
EV to Capital Employed
0.55
EV to Sales
0.78
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1.78%
ROE (Latest)
-5.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bearish
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
23.70
19.90
19.10%
Operating Profit (PBDIT) excl Other Income
0.50
-0.70
171.43%
Interest
1.00
0.70
42.86%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.30
-2.10
38.10%
Operating Profit Margin (Excl OI)
-12.90%
-81.10%
6.82%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 19.10% vs 38.19% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 38.10% vs 41.67% in Dec 2022
About Tissue Regenix Group Plc 
Tissue Regenix Group Plc
Pharmaceuticals & Biotechnology
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.
Company Coordinates 
Company Details
2 Astley Way, Astley Lane Industrial Estate LEEDS None : LS26 8XT
Registrar Details






